We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genomic Test Guides Chemotherapy Decisions in Older Breast Cancer Population

By LabMedica International staff writers
Posted on 11 Jun 2025

Findings from a study presented at the 2025 American Society of Clinical Oncology Annual Meeting suggest that a novel genomic assay could support treatment decision-making by identifying older patients who might benefit from chemotherapy for high-risk early-stage breast cancer. More...

The study, conducted by researchers at Baptist Health Miami Cancer Institute (Miami, FL, USA), evaluated the effectiveness of Agendia’s (Amsterdam, Netherlands) MammaPrint 70-gene assay in informing treatment plans for patients aged 70 and above diagnosed with early-stage breast cancer.

The research utilized data from the FLEX registry, a large, prospective, real-world observational study designed to collect clinical and genomic information from early-stage breast cancer patients who undergo MammaPrint testing. The objective was to understand how the assay’s results influence therapeutic decisions and long-term outcomes across varied clinical environments and demographics. The analysis included over 3000 patients under the age of 70 and slightly more than 1000 patients aged 70 or older, alongside descriptive data on tumor and patient characteristics.

The study found that older patients were significantly less likely than younger ones to have high-grade tumors or lymph node involvement. Moreover, the MammaPrint risk profile indicated a greater share of low genomic risk tumors, including ultralow- and low-risk categories, among the older cohort. Among patients with high-risk tumors, classified as High 1 or High 2 by MammaPrint, older individuals were less likely to receive chemotherapy compared to their younger counterparts. Notably, this trend persisted even when the tumors showed high genomic risk.

In terms of clinical outcomes, older patients with MammaPrint high-risk tumors, particularly those categorized as High 2, tended to experience improved 3-year relapse-free intervals when treated with chemotherapy versus endocrine therapy alone. These findings indicate that MammaPrint can play a valuable role in personalizing chemotherapy decisions for older women by identifying those who may gain a survival benefit from treatment and helping to avoid unnecessary chemotherapy in those with low-risk profiles.

Related Links:
Agendia 
Baptist Health Miami Cancer Institute


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.